C4 THERAPEUTICS, INC. (CCCC)
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
C4 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
Via Announces First Quarter 2026 Results
Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights
Loblaw Releases 2025 Live Life Well® Report Highlighting Progress in Sustainability, Community Support, and Social Impact
Ralliant Reports First Quarter 2026 Results and Raises Full Year Guidance
Ecolab Delivers Strong Performance and Impact
American Shared Hospital Services Announces First Quarter 2026 Financial Results Conference Call
Brookdale to Present at the Bank of America Global Healthcare Conference and the RBC Capital Markets Global Healthcare Conference
Veritone Reports First Quarter 2026 Results, Reaffirms 2026 Guide of $130-$145 million in Revenue in Fiscal 2026
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
CIBC Innovation Banking Provides Growth Capital to EnsoData
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Vestis Reports Second Quarter 2026 Results and Increases Full Year 2026 Outlook
Loblaw publie le Rapport Vivre bien, vivre pleinement 2025 qui souligne ses progrès en développement durable, en soutien communautaire et en impact social